OneSource Speci, a company in the Pharmaceuticals industry, reported revenue of ₹516 crore and net profit of ₹57 crore for the September 2026 quarter.
OneSource Speci. (NSE: ONESOURCE) closed at ₹1,609.30 on 20 Nov 2026, down 3.8% over the past year. Its market capitalisation is ₹18,455 crore and it trades at 1613.2 times earnings.
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.